Cited by 191Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Neuronal Hypertrophy in Asymptomatic Alzheimer Disease

Open access
Iacono, Diego, O'Brien, Richard, Resnick, Susan M., Zonderman, Alan B., Pletnikova, Olga, Rudow, Gay, An, Yang, West, Mark J. +2 more·2008·Journal of Neuropathology & Experimental Neurology

Abstract

The pathologic changes of Alzheimer disease (AD) evolve very gradually over decades before the disease becomes clinically manifest. Thus, it is not uncommon to find substantial numbers of Abeta plaques and neurofibrillary tangles in autopsy brains of older subjects with documented normal cognition, a state that we define as asymptomatic AD (ASYMAD). The goal of this study is to understand the morphometric substrate of ASYMAD subjects compared with mild cognitive impairment and definite AD cases. We used designed-based stereology to measure the volumes of neuronal cell bodies, nuclei, and nucleoli in 4 cerebral regions: anterior cingulate gyrus, posterior cingulate gyrus, primary visual cortex, and CA1 of hippocampus. We examined and compared autopsy brains from 4 groups (n = 15 each) of participants in the Baltimore Longitudinal Study of Aging: ASYMAD, mild cognitive impairment, AD, and age-matched controls. We found significant hypertrophy of the neuronal cell bodies, nuclei, and nucleoli of CA1 of hippocampus and anterior cingulate gyrus neurons in ASYMAD subjects compared with control and mild cognitive impairment cases. In the posterior cingulate gyrus and primary visual cortex, the hypertrophy was limited to the nuclei and nucleoli. The hypertrophy of cortical neurons and their nuclei and nucleoli in ASYMAD may represent an early reaction to the presence of neurotoxic Abeta or tau, or a compensatory mechanism that prevents the progression of the disease into dementia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/nen.0b013e3181772794

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AsymAD individuals have neuritic plaque and NFTs Braak stages at autopsy comparable to those of AD subjects with dementia.

    “These individuals have neuritic plaque and NFTs Braak stages at autopsy comparable to those of AD subjects with dementia, and the literature refers to them as resilient [31], Nondemented with AD Neuropathology (NDAN) [83], or asymptomatic AD (AsymAD) [22, 42].”

    From Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer’s disease (2024) · cites this paper as [42]

    The Results report that asymptomatic AD (ASYMAD) and dementia-diagnosed AD subjects did not differ significantly in CERAD neuritic plaque classification. They also report a significant difference in Braak NFT staging, so the claim that both measures were comparable is not supported. (LLM, conf=0.94)

    Experimental — accuracy not yet measured
  • AsymAD brains exhibit no signs of notorious synaptic or neuronal deterioration.

    “studies have demonstrated that AsymAD brains exhibit no signs of notorious synaptic or neuronal deterioration [8, 42, 73]”

    From Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer’s disease (2024) · cites this paper as [42]

    The Abstract reports neuronal hypertrophy in several regions of ASYMAD brains, supporting a contrast with neuronal shrinkage in those measured cells. But the paper does not establish an absence of neuronal deterioration generally or measure synaptic deterioration; the Introduction discusses possible neuronal and synaptic derangements despite preserved cognition. Page numbers are not available in our copy. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer_s disease. Ann Neurol 2000;47:430Y39
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Third Edition-Revised (DSM-II-R). Washington, DC: American Psychiatric Press, Inc., 1987
  3. Luna G. AFIP Manual of Histologic Staining Techniques. 3rd ed. New York, NY: McGraw-Hill Publications, 1968
  4. Lorente De No ´R. Studies on the structure of the cerebral cortex. I. The area entorhinalis. J Psychol Neurol 1933;45:381Y438 45. StereoInvestigator System [computer program]. Version

Cited by

Sorted by citations

Authors
Iacono, D., O'Brien, R., Resnick, S. M., Zonderman, A. B., Pletnikova, O., Rudow, G., An, Y., West, M. J., Crain, B., & Troncoso, J. C.
Affiliations
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
  • Aarhus University (DK)
Corresponding author
Troncoso, Juan C.
Venue
Journal of Neuropathology & Experimental Neurology
Published
2008-06
Volume
67
Issue
6
Pages
578-589
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
OpenAlex
W2097399504
Cited by
188
References
67
Citations by year
2026: 6 · 2025: 16 · 2024: 15 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 6 · 2019: 14 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 10 · 2014: 13 · 2013: 17 · 2012: 8
FWCI
6.09
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuropathology & Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Burroughs Wellcome Fund
  • Johns Hopkins University
  • National Institutes of Health
  • National Institute on Aging (K23AG034550, Z01AG000191, P50AG005146, AG 05146)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
neuronal hypertrophy, hippocampal CA1, anterior cingulate cortex, posterior cingulate cortex, primary visual cortex, mild cognitive impairment, amyloid plaques, neurofibrillary tangles, stereology
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition Disorders, Humans, Hypertrophy, Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review